Isabel Blancas

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Hope S. Rugo, Joyce O’Shaughnessy, F Boyle et al. · Annals of Oncology · 2022 · 109 citations · Full text

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 32 citations · Full text

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

Peter A. Fasching, Aditya Bardia, Vanesa Quiroga et al. · Journal of Clinical Oncology · 2022 · 30 citations

Breast Oncology, Gynecology, Pharmacotherapy +22

TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression

Araceli López-Tejada, Carmen Griñán‐Lisón, Adrián González-González et al. · International Journal of Biological Sciences · 2022 · 19 citations · Full text

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Manuel Ruíz Borrego et al. · EClinicalMedicine · 2024 · 19 citations · Full text